ImmunoScape

ImmunoScape is a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. The companys proprietary Deep Immunomics technology platform enables highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid tumors. ImmunoScape has multiple discovery programs ongoing and will be progressing towards IND-enabling studies and entry into the clinic. To learn more, visit us at immunoscape.com and follow us on Twitter @immunoscape

Immunotherapy,mass cytometry,immunomonitoring,t cell antigens,oncology,infectious diseases,autoimmune diseases,cytographer,immunoprofiling,cytof,neoantigen,biomarker,and vaccine

Immunoscape operates in the Biotechnology research industry.

Immunoscape's revenue is 11m - 100m

Immunoscape has 11 - 50 employees.